Answers are grounded in this paper and cite their sources.
INTRODUCTION: Lu]Lu-prostate-specific membrane antigen (PSMA) radioligand therapy can improve outcomes in patients with metastatic castration-resistant prostate cancer, though response is highly variable in clinical practice. We performed a systematic review and meta-analysis to evaluate the prognostic value of pre-therapeutic PSMA PET-derived imaging biomarkers to better inform patient selection for treatment. METHODS: ), PSMA tumour volume (PSMA-TV), total lesional uptake (PSMA-TLU), and total lesional quotient (PSMA-TLQ). Outcomes were overall survival (OS), prostate-specific antigen progression-free survival, and 50% reduction in prostate-specific antigen levels (PSA50). Random-effects meta-analyses were performed, prioritising multivariable-adjusted effect estimates. Risk of bias was assessed using the Quality In Prognosis Studies tool. RESULTS: showed limited prognostic value. Most studies were retrospective and were classified as having moderate risk of bias. CONCLUSION: Lu]Lu-PSMA therapy.
No takes yet. Share an insight, caveat, or question.
Molin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: